Key Points
- CRISPR Therapeutics insider Naimish Patel sold 3,786 shares on May 29 at an average price of $55.62, totaling about $210,577. The sale reduced his stake by 16.36% and was tied to tax withholding from vested equity awards.
- CRSP shares were trading around $54.19, with the company carrying a market cap of $5.23 billion and a 52-week range of $36.08 to $78.48. The stock also had a negative P/E ratio and higher volatility, reflected by a beta of 1.74.
- Analysts remain cautiously positive on CRISPR Therapeutics, with a consensus rating of “Moderate Buy” and an average price target of $65.47. Recent earnings showed a loss of $1.28 per share and revenue of $1.46 million for the quarter.
CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) insider Naimish Patel sold 3,786 shares of the business's stock in a transaction on Friday, May 29th. The stock was sold at an average price of $55.62, for a total transaction of $210,577.32. Following the transaction, the insider owned 19,357 shares of the company's stock, valued at approximately $1,076,636.34. The trade was a 16.36% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Naimish Patel also recently made the following trade(s):
- On Monday, March 16th, Naimish Patel sold 3,150 shares of CRISPR Therapeutics stock. The stock was sold at an average price of $48.26, for a total transaction of $152,019.00.
CRISPR Therapeutics Stock Performance
Shares of CRSP stock opened at $54.19 on Tuesday. The company has a current ratio of 17.97, a quick ratio of 17.96 and a debt-to-equity ratio of 0.32. The firm has a fifty day moving average price of $51.51 and a 200 day moving average price of $53.11. The company has a market cap of $5.23 billion, a P/E ratio of -8.71 and a beta of 1.74. CRISPR Therapeutics AG has a 12 month low of $36.08 and a 12 month high of $78.48.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its earnings results on Tuesday, March 31st. The company reported ($1.28) EPS for the quarter. The firm had revenue of $1.46 million for the quarter. CRISPR Therapeutics had a negative return on equity of 25.66% and a negative net margin of 13,856.54%. Sell-side analysts predict that CRISPR Therapeutics AG will post -4.96 earnings per share for the current fiscal year.
Institutional Investors Weigh In On CRISPR Therapeutics
A number of hedge funds have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. lifted its position in CRISPR Therapeutics by 5.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,516 shares of the company's stock valued at $228,000 after purchasing an additional 180 shares during the period. Cerity Partners LLC increased its holdings in CRISPR Therapeutics by 3.0% in the second quarter. Cerity Partners LLC now owns 6,541 shares of the company's stock valued at $318,000 after buying an additional 190 shares in the last quarter. Peapack Gladstone Financial Corp increased its holdings in CRISPR Therapeutics by 3.0% in the second quarter. Peapack Gladstone Financial Corp now owns 6,973 shares of the company's stock valued at $339,000 after buying an additional 200 shares in the last quarter. Optiver Holding B.V. increased its holdings in CRISPR Therapeutics by 71.4% in the third quarter. Optiver Holding B.V. now owns 504 shares of the company's stock valued at $33,000 after buying an additional 210 shares in the last quarter. Finally, US Bancorp DE increased its holdings in CRISPR Therapeutics by 4.5% in the third quarter. US Bancorp DE now owns 5,777 shares of the company's stock valued at $374,000 after buying an additional 249 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company's stock.
Wall Street Analyst Weigh In
Several equities analysts have issued reports on CRSP shares. Needham & Company LLC upped their price objective on shares of CRISPR Therapeutics from $80.00 to $82.00 and gave the company a "buy" rating in a research note on Friday, February 13th. Evercore restated an "outperform" rating and issued a $76.00 price objective on shares of CRISPR Therapeutics in a research note on Monday, May 11th. Citigroup reiterated a "market outperform" rating on shares of CRISPR Therapeutics in a research note on Wednesday, May 27th. TD Cowen increased their target price on shares of CRISPR Therapeutics from $40.00 to $45.00 and gave the stock a "hold" rating in a research note on Friday, February 13th. Finally, Piper Sandler reiterated an "overweight" rating and set a $110.00 target price (up from $105.00) on shares of CRISPR Therapeutics in a research note on Tuesday, March 17th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $65.47.
View Our Latest Stock Analysis on CRISPR Therapeutics
About CRISPR Therapeutics
(
Get Free Report)
CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.
Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
